DOCSLIB.ORG

Caring and Curing Annual Report 2004

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Caring and Curing Annual Report 2004 CARING AND CURING artis Nov 2004 AL REPORT ANNUAL REPORT 2004 www.novartis.com ANNU 10 000-liter extraction vessel, Novartis pharmaceutical production; Basel, Switzerland azil á, Br ortaleza, Cear en's Hospital Albert Sabin; F Back cover: Children's Hospital Albert Sabin; Fortaleza, Ceará, Brazil Childr OUR MISSION We want to discover, develop and successfully market innovative products to cure diseases, to ease suffering and to enhance the quality of life. We also want to provide a shareholder return that reflects outstanding performance and to adequately reward those who invest ideas and work in our company. GROUP OVERVIEW 2 Financial Highlights 3 News in 2004 5 Letter from Daniel Vasella 10 Divisions and Business Units Pharmaceuticals 40 Consumer Health 50 Corporate Citizenship 52 Commitment to Patients 66 Commitment to Our People 72 Commitment to Health, Safety and Environment 79 Commitment to Business Conduct 85 Corporate Governance Commitment to Corporate Governance 104 Board of Directors 110 Executive Committee 112 Business Unit Heads FINANCIAL OVERVIEW 115 Financial Report 194 Key Dates for 2005 195 Contact Addresses Front cover: Shanghai Children's Medical Center, Shanghai Second Medical University; Shanghai, China NOVARTIS GROUP 1 FINANCIAL HIGHLIGHTS Keyfigures Net sales, operating income and net income (in USD millions unless indicated otherwise) (in USD millions) 30 000 2004 2003 Net sales 28 247 24 864 25 000 Operating income 6539 5 889 Net income 5767 5 016 20 000 Return on sales (%) 23.1 23.7 15 000 Research and development 4207 3 756 Research and development 10 000 as % of net sales 14.9 15.1 Free cash flow 3359 3 628 5000 Number of employees 81 392 78 541 0 2000 2001 2002 2003 2004 Net sales * Operating income * Net income * in 2000 excluding discontinued Agribusiness Division Shareinformation Earnings per share (USD) and pay-out ratio (%) USD 2.4 % 2004 2003 Return on average equity (%)* 18.0 17.1 2.0 40 Earnings per share (USD)* 2.36 2.03 Operating cash flow per share (USD) 2.75 2.69 1.6 32 ADS price at end of year (USD) 50.54 45.89 1.2 24 Share price at end of year (CHF) 57.30 56.15 Pay-out ratio based on outstanding 0.8 16 shares (%) 39 39 0.4 8 * Average number of shares outstanding in 2004: 2 447 954 717 (2003: 2 473 522 565) 00 2000 2001 2002 2003 2004 Earnings per share in USD Dividend pay-out ratio in % of net income Net sales by division 2004 2003 Operating income by division 2004 2003 Pharmaceuticals Pharmaceuticals 65% 64% 82% 77% Consumer Health Consumer Health 35% 36% 18% 23% 2 NOVARTIS GROUP NEWS IN 2004 GROUP PERFORMANCE Novartis delivers record net sales and net income. Group net sales grow 14% (+9% in local currencies) and net income 15%, driven by strong organic growth at both Pharmaceuticals and Consumer Health. PHARMACEUTICALS Double-digit net sales growth continues to outpace the market. Further market share gains registered in key countries. Operating income expands faster than net sales due to strong organic growth and productivity improvements. CONSUMER HEALTH Net sales advance 10% (+5% in local currencies), driven by focus on strategic brands and new product launches, particularly at OTC and CIBA Vision. Sandoz performance adversely affected by comparison with strong 2003, and by price competition. PIPELINE Novartis leads pharmaceutical industry with 13 regulatory approvals in US since 2000. Seven approvals in major markets in 2004. Industry-leading pipeline with 75 projects in clinical development, of which 52 in Phase II, Phase III or in registration. RESEARCH Novartis Institutes of BioMedical Research double scientific staff at Cambridge headquarters, with emphasis on biology of diseases with high unmet medical need, and strong commitment to external collaboration and strategic partnerships. CORPORATE CITIZENSHIP In 2004, Novartis is able to contribute USD 570 million to patients in need through access to medicine programs. DIVIDEND A dividend increase to CHF 1.05 per share (+5%) will be proposed to shareholders, reflecting the strong organic net sales growth and improved profitability. NOVARTIS GROUP 3 artis Animal Health; Shanghai, China 4 NOVARTIS GROUP Nov LETTER FROM DANIEL VASELLA Daniel Vasella, M.D. Dear Shareholder: I am pleased to report strong business performance in our ninth business year, which ended with yet another record result and market share gains. Let me summarize the key 2004 figures: • Group net sales increased 14% (9% in local currencies) to USD 28.2 billion – Pharmaceuticals net sales rose 15% (10% in local currencies) – Consumer Health net sales gained 10% (5% in local currencies) • Group operating income advanced to USD 6.5 billion (+11%), • Net income growth of 15% to USD 5.8 billion • Earnings per share USD 2.36 (+16%) Innovation and a focus on patients, core elements of our strategy, resulted in another record performance These record results reflect our emphasis on sustainable, organic growth, a product of our consistent innovation strategy and the skills and commitment of over 81 000 associates worldwide. The Pharmaceuticals division, again led by our can- cer and cardiovascular franchises, posted a double-digit rise in sales, with market share expanding globally. These successes were realized in a challenging health-care mar- ket characterized by cost-containment measures in many parts of the world. NOVARTIS GROUP 5 LETTER FROM DANIEL VASELLA In 2004, we increased overall R&D investments by Among these are: 12% to USD 4.2 billion • LAF237, the first of a new class of “incretin enhancers,” Our pharmaceutical research and development (R&D) oral antidiabetic agents that indirectly increase the blood expenditure ranked as one of the highest in the industry, glucose regulating hormone GLP-1. Phase III trial data relative to sales (18.8%), with outlays of USD 3.5 billion. for LAF237 are expected during the latter part of 2005. This investment allowed us to complete construction of new laboratories, and hire more than 800 scientists at our • SPP100 is the first in a new antihypertensive class new research headquarters in Cambridge, MA. New or called “renin inhibitors.” Elevated renin levels increase enhanced platforms in biology and chemistry, paired with the risk of myocardial infarction and renal damage. So, scientific leadership, not only fortified fundamental and SPP100 has the potential for improved end-organ pro- applied research but also improved the compound selec- tection. Phase III data are expected in 3Q 2005. tion process, speeding up pipeline throughput. The Novartis Institutes for BioMedical Research • FTY720, an immunomodulator with a novel mechanism (NIBR) continue to focus their efforts on tractable biolog- of action, has recently completed Phase II studies as an ical targets and selected disease areas with high unmet oral treatment for multiple sclerosis, showing a reduc- medical needs, striving to bring novel medicines rapidly to tion of brain lesions and a significantly reduced relapse patients. To achieve this objective, we are intensifying our rate for MS patients treated. efforts to elucidate the function of specific human genes identified by the Human Genome Project. While structur- • PTK787 is an anticancer drug that inhibits all known al blueprints for these genes are now available, in most angiogenesis factors involved in cancer. Submission for cases the genes’ primary role in the body and their poten- US regulatory approval is planned for the second half of tial involvement in disease remain unknown. “Functional- 2005. izing” the genome is a vast undertaking – one beyond the means and resources of any single company. According- • AMN107 is our new, most selective BCR-ABL inhibitor, ly, we have forged dozens of collaborations, completing a potentially more effective follow-up compound for our 48 alliances with industry and 100 with academia. revolutionary medicine Gleevec/Glivec.Phase II studies will begin in the first half of 2005. Pipeline of new drugs is one of the industry’s strongest Promising new compounds bring hope to patients Our pharmaceutical development pipeline is one of the As a physician, I often witnessed the hope that R&D best with 75 compounds, 52 of which are in advanced brought to patients, especially in life-threatening situa- development or registration. Over the past few years, tions. New treatments that can reduce suffering and high Novartis has maintained its leading position in R&D pro- health-care costs are needed for the more than 10 million ductivity. Novartis has received 13 US approvals since people diagnosed with cancer annually, and for those suf- 2000, the highest figure of any Top Ten global pharma- fering from incapacitating Alzheimer’s dementia, diabetes ceutical company. Of particular importance are first- and cardiovascular disease, all on the rise. in-class compounds and, currently, 7 of our 10 highly It is a fact that a good profit outlook is a precondition innovative compounds in mid-to-late-stage development for any industrial R&D activities. In turn intellectual prop- belong to this group. erty protection is the only way to ensure the open sharing of research findings without fear of copying, and to be cer- tain that there is a potential to earn an adequate return from successful projects. Therefore strong intellectual 6 NOVARTIS GROUP property rights are a foundation for sustained innovation A medicine-based business portfolio and allow us to continue to invest in R&D despite long lead As a company, we want to discover, develop and market times of 12–15 years. In this context I welcome the deci- medicines that are best suited for specific conditions. This sion by India to introduce patent protection in 2005, includes innovative prescription medicines, which some- which, I believe will accelerate development of an innova- times are breakthroughs and have the power to change tive domestic Indian pharmaceutical industry and encour- the way medicine is practiced.
Load more

Recommended publications
  • From Sweets to Science
    From Sweets to Science The Transformation of 250 Massachusetts Avenue 2 From Sweets to Science Transforming an almost 80-year-old candy factory into a state-of-the-art laboratory to enable, stimulate, and excite world-class scientists to research and discover innovative drugs, took the dedication, creativity, and inexhaustible energy of hundreds of people. The former candy factory owned and operated by the New England Confectionery Company (NECCO), at 250 Massachusetts Avenue, was identified as the headquarters of the Novartis Institutes for BioMedical Research (NIBR) in August 2002. Novartis communicated to an experienced team of architects and designers at The Stubbins Associates, Inc., the need to “invent” an interior environment that would encourage, foster, and facilitate collaboration and the exchange of ideas and knowledge between scientists. To operate as an efficient and productive organization, the building would have to: • Emphasize openness and transparency • Promote informal social interaction • Integrate interacting scientific disciplines • Make an efficient use of space • Energize the scientists The architects and designers planned a renovation that set new standards of laboratory design. John Moriarty & Associates, Inc. was contracted to do the job, and they fulfilled their task on budget and in record time. The NIBR global headquarters has been occupied and operational since April 2004. From Sweets to Science 1 History of 250 Massachusetts Avenue Until the middle of the 19th century, the land the former NECCO building occupies was tidal marsh. In 1853, railroad tracks were laid, and in 1890, Massachusetts Avenue was FACT: constructed, spurring commercial development. 2,000 miles of telephone and data cables The former NECCO building and its accompanying buildings were completed and occupied installed in 1927 and became the world headquarters for NECCO.
    [Show full text]
  • On Candy Hearts
    Academic Exchange Quarterly Winter 2018 ISSN 1096-1453 Volume 22, Issue 4 To cite, use print source rather than this on-line version which may not reflect print copy format requirements or text lay-out and pagination. This article should not be reprinted for inclusion in any publication for sale without author's explicit permission. Anyone may view, reproduce or store copy of this article for personal, non-commercial use as allowed by the "Fair Use" limitations (sections 107 and 108) of the U.S. Copyright law. For any other use and for reprints, contact article's author(s) who may impose usage fee.. See also electronic version copyright clearance CURRENT VERSION COPYRIGHT © MMXVIII AUTHOR & ACADEMIC EXCHANGE QUARTERLY Critiquing the Sweet “Somethings” on Candy Hearts Michelle Napierski-Prancl, Russell Sage College, Troy, NY Michelle Napierski-Prancl, PhD, is Associate Professor of Sociology and Chair of the Department of History and Society at Russell Sage College. Abstract After establishing the ubiquitous nature of candy conversation hearts in our popular culture and Valentine’s Day celebrations, this paper provides an outline of a simple classroom assignment that can be used to achieve three possible objectives: to analyze cultural messages about love; to illustrate the research method of content analysis; and to challenge students to construct their own cultural critique of the messages on candy hearts and the age group most likely to give and receive them on Valentine’s Day. Candy Hearts in our Popular Culture It is one of the oldest ways in our popular culture for Americans to share their sweet nothings: the candy conversation heart.
    [Show full text]
  • Necco Dispute Clears Hurdle in Bankrtuptcy Court
    CHESTO MEANS BUSINESS Necco dispute clears hurdle in bankruptcy court By Jon Chesto Globe Staff, July 24, 2019, 8:25 p.m. The NECCO factory in Revere. (ARAM BOGHOSIAN FOR THE BOSTON GLOBE) The Sky Bar, Sweethearts, and Candy Buttons all have new owners, as does the shuttered Necco factory in Revere that had once churned out a sea of confections that would make Willy Wonka proud. But the roughly $10 million left over from the sale of Greater Boston’s last great candy maker? That remains untouched amid a dispute between a bankruptcy trustee and Necco’s former parent company. The trustee, Harold Murphy, just won a significant victory in US bankruptcy court in Boston. Judge Melvin Hoffman essentially denied nearly every effort by Necco’s former parent firm, Ares Capital, to dismiss a case brought by Murphy. Ares had acquired a previous private-equity owner of Necco, ACAS. The case now moves forward, with a trial expected next year. Murphy has sued Ares, claiming the investment firm and its predecessor piled debt onto the Necco business while running the once massive candy empire into the ground. Murphy wants Necco’s former suppliers and other unsecured creditors to be fully reimbursed for the bills left unpaid by the candy company’s demise last year, a figure that totals at least $20 million. Murphy is trying to persuade the judge to knock Ares from its position as first in line for the proceeds from the Necco sale. (Ares was a secured creditor as well as the former owner.) He also claims that ACAS enriched itself from Necco over the years, even as the candy business bled tens of millions.
    [Show full text]
  • Cambridge Historical Commission Objects Collection
    Cambridge Historical Commission Objects Collection Cambridge Historical Commission 831 Massachusetts Avenue Cambridge, MA 02139 Provenance: Multiple sources—see individual items Collection ID: OBJ01 Dates: c. 1890s-1980s Extent: 70 items in 9 boxes and 1 oversize folder Finding aid by: Meta Partenheimer, June 2017. Updated by Brittany Fox and Emily Gonzalez, November 2019. Access: Collection is available for research under the CHC rules of use Collection Description: Collection of objects relating to various aspects of Cambridge history. Historical context, if known, is provided. Related Materials: Cambridge Ephemera Collection (CHC001) Box list: Box 1: Item 1. Cambridge City Hall Vase, glazed ceramic, 5” in height, made in Germany, nd Purchase, ca. 2001 [location: temporarily removed to CHC conference room] Item 2. Roughcast sample, “from under the flush boarding,” taken from 7 Dana Street Aggregate of sand, rubble, and possibly horsehair, ~2.50 x 2.25”, nd Item 3. Unfired clay pot from 145 Elm Street (Ivory Sands House), 1.8” in height, nd Gift of Ed Seldin Item 4. Glazed clay pot likely from 145 Elm Street (Ivory Sands House), 1.8” in height, nd Item 5. Notebook (blank) with cover showing image of Boylston Street in Cambridge, paper and wire, 2.5 x 3.5”, ca. 1960s Gift of Frances Antupit, 2002 Item 6. Key Chain of the Harvard Square Business Association, metal, 1.6 x 1.3”, ca. 1985 Gift of Frances Antupit, 2002 Item 7. Longfellow Home Vase, glazed ceramic, made in Germany, 5.25” in height, nd Underside is stamped: “Made in Germany for Wm. Scott & Co., Cambridgeport, Mass.” Item 8.
    [Show full text]
  • Caring and Curing
    Caring and Curing Annual Report 2002 Novartis www.novartis.com Annual Report 2002 …molecules for medicines… Martin Klumpp, PhD, Lukas Leder, PhD, and Aline Tirat, Novartis Lead Discovery Center, Basel, Switzerland ...writing in sand... Sarvodaya Pre-School, Paluchera, Sri Lanka Contents Financial Highlights2 News in 20023 Letter from Daniel Vasella5 Amazing Patient Stories9 Division and Product Review Pharmaceuticals14 Joining Forces in the Quest for Cures22 Consumer Health29 Corporate Citizenship37 Animal Welfare46 Health, Safety and Environment49 Human Resources60 Corporate Governance Corporate Governance67 Board of Directors79 Executive Committee82 Business Unit Heads84 Financial Report Operating and Financial Review87 Equity Strategy and Share Information98 Group Consolidated Financial Statements and Notes104 Principal Companies138 Reconciliation to US GAAP140 Financial Statements of Novartis AG151 Due Dates for Reporting and Contacts157 Front cover: Svenja, a young eczema patient during an examination at the Center for Dermatology, University of Frankfurt am Main, Germany. Back cover: Svenja with her brother, Jan Patrick in the pediatric ward. Novartis Group 1 Financial Highlights Sales CHF millions Free cash flow2 CHF millions 2002 32 412 2002 4 463 2001 31 643 2001 4 073 20001 29 112 20001 3 254 Operating income CHF millions Research and development CHF millions 2002 7 887 2002 4 339 2001 7 277 2001 4 189 20001 6 727 20001 4 011 Net income CHF millions Employees at year end 2002 7 313 2002 72 877 2001 7 024 2001 71 116 20001 6
    [Show full text]
  • View the Gala Program
    Global Citizen Award presented to Professor Klaus Schwab September 23, 2010 The Plaza • New York International Advisory Board Lt Gen Brent Scowcroft, USAF (Ret.), Chairman National Security Advisor to Presidents Gerald Ford and George H. W. Bush Senator Chuck Hagel Mr. Thomas H. Glocer The Rt. Hon. Lord Robertson of Chairman, Atlantic Council of the CEO, Thompson Reuters Port Ellen United States Mr. Francisco Gonzalez Former Secretary General of NATO Mr. Frederick Kempe Chairman & CEO, BBVA Ms. Güler Sabanci President & CEO, Atlantic Council Dr. James Goodnight Chairman & Managing Director, Members: Chief Executive Officer, SAS Haci Ömer Sabanci Holding A.S. Dr. Josef Ackermann Mr. Muhtar Kent Mr. Stephen A. Schwarzman Chairman of the Management Board Chairman & CEO, Chairman, CEO & Co-Founder, & the Group Executive Committee, The Coca-Cola Company The Blackstone Group Deutsche Bank AG President Aleksander Kwasniewski Sir Martin Sorrell H.E. Shaukat Aziz Former President of Poland Group Chief Executive, WPP Group PLC Former Prime Minister of Pakistan Mr. Jean Lemierre President Jose Maria Aznar Former President, The European Bank Mr. Robert J. Stevens Former Prime Minister of Spain for Reconstruction and Development Chairman, President & CEO, Lockheed Martin Dr. Zbigniew Brzezinski Mr. Alexey A. Mordashov National Security Advisor to President CEO, Severstal Mr. Sergey A. Taruta Jimmy Carter Chairman of the Board, Mr. Bob Moritz Industrial Union of Donbass Mr. Victor L. L. Chu U.S. Chairman & Senior Partner, Chairman, First Eastern Investment PricewaterhouseCoopers Dr. Gunter Thielen Group Chairman of the Supervisory Board, Mr. Rupert Murdoch Bertelsmann AG Mr. Richard Edelman Chairman & CEO, News Corporation President & CEO, Edelman Mr.
    [Show full text]
  • Revere Mayor Responds to Soaring Unemployment in His City - the Boston Globe
    6/30/2020 Revere mayor responds to soaring unemployment in his city - The Boston Globe Revere mayor responds to soaring unemployment in his city Reliance on the hospitality industry has hobbled the city's economy By Jon Chesto Globe Staff, Updated June 29, 2020, 8:19 p.m. A couple walks on Revere Beach, Saturday, May 16, 2020, in Revere, Mass. (AP Photo/Michael Dwyer) MICHAEL DWYER/ASSOCIATED PRESS The COVID-19 pandemic has slammed the brakes on the Revere Renaissance. In 2019, the city’s fortunes were on the rise. Amazon agreed to lease the former Necco candy factory, where it still plans to hire hundreds for a new “delivery station.” Residents found plentiful hospitality jobs, as the hotel and restaurant businesses boomed in Greater Boston and Wynn Resorts opened a giant casino in nearby Everett Revere’s https://www.bostonglobe.com/2020/06/29/business/revere-mayor-responds-soaring-unemployment-his-city/ 1/4 6/30/2020 Revere mayor responds to soaring unemployment in his city - The Boston Globe Greater Boston and Wynn Resorts opened a giant casino in nearby Everett. Revere s unemployment rate was 3 percent, essentially matching the state average. Nearly anyone who wanted a job could get one. Then the coronavirus hit. Amazon is moving ahead, but much of Revere’s economy is falling behind. Many of the region’s hospitality jobs are gone, and some won’t be coming back. The latest figures show Revere now has the second highest unemployment rate of any city in the state. Its jobless rate of 25.6 percent puts it behind only Lawrence.
    [Show full text]
  • Here's a List of Choices of Candy Products Made by Members of The
    Here's a list of choices of candy products made by members of the Bakery, Confectionery, Tobacco Workers and Grain Millers International Union (BCTGM); snack foods by members of the United Food and Commercial Workers (UFCW); or fruit and nuts from members of the United Farm Workers of America (UFW). As with a lot of traditionally union-made products, more are being cross-produced (union-non-union; US-Mexico), so be sure to read labels to ensure that your candy is union-made in the United States. If you know of any union-made candy missing from this list, please leave a comment below and we will add it! Hershey Products Necco (New England Confectionery Company) Hershey Kisses* Sweethearts Hershey Syrups Mary Jane Peanut Butter Chews Hershey Milk Chocolate Bar* NECCO Wafers/Necco Wafer Smoothies Hershey Milk with Almond Bars Sky Bar Hershey Special Dark Bars Clark Bar Hershey Nuggets Canada Mints Rolo Candy Cupboard Hershey Kissables Thin Mints Kit Kat Bars NECCO Assorted Junior Wafers Carmello Bar Clark Junior Laydown Bag Cadbury Fruit & Nut Bar Mary Jane Laydown Bag Cadbury Roast Almond Bar Haviland Cadbury Royal Dark Bar Cadbury Dairy Milk Bar Ghiradelli Chocolates Hershey Symphony Bar with Toffee All filled & non filled squares Non pariels See's Candy Chocolate chips Gimbals Fine Candies Nestle JellyBeans Nestle Treasures Cherry Hearts Laffy Taffy Scotty Dogs Kathryn Beich specialty candy Baby Ruth* Jelly Belly's Candy Company Butterfinger* Jelly Bellies - also made in a non-union plants in Chicago/Taiwan Pearson's Nips Chocolate Dutch Mints Famous Old Time Candies (gourmet chocolates) Chocolate Temptations Dimples Pearson's Candy Co.
    [Show full text]
  • Official Transcript Request Necco
    Official Transcript Request Necco tortiously.Explosive AulicClair reaccustomEdwin always stormily. spews Morphotichis Albinoni and if Ingelbert bug-eyed is Antonius six or sobbed benefited advisedly. her conchie whiffle or cloud Illinois State otherwise with Charlene Necco in attendance. COVID-19 Resources Greater Ohio Virtual School. Be Mine Nope SweetHeart Candies Hard To special This. PEOPLE v 74 CASES OF LIFE SAVER CANDY DROPS. Laid-off NECCO workers sue company. Searching with your location helps find jobs closer to insure Use my. How can Apply and Graduate Admission at UCO Applying for. Necco candy chooses gay couple for Valentine's ad attempts to. Barney and Jim Patrick began according to submit transcript from Frank's. Degrading the Grading Myths A Primer of Alternatives to. Jcainneccoorg 270 505-413 Position Qualifications 21 years of literary Bachelor's degree that a human services related field should a. 060517 Revere City Council Meeting YouTube. Summaries financial aid award academic transcripts andor school schedules. And per your grid I moved up your meeting on judicial. The Joy Luck Club Western School Of Technology. There on over 12 opportunity development specialist i careers in Ashland KY waiting stage you next apply. State college transcript also said students will be entitled upon high request. Incoming Transfer Students In order to again transfer credits from his prior institutions we both receive your official transcripts Please shed any prior. Saf-T-Pops Spangler Canes Circus Peanuts Necco Wafers Sweethearts. Necco Wafers reportedly taste like 'drywall' but fans are. Transfer Credits Transfer Resource Center University of. To review eligibility requirements and elbow for assistance please visit.
    [Show full text]
  • ANNUAL REPORT 2012 Contents OUR Mission
    ANNUAL REPORT 2012 cONTENTs OUR missiON GROUP REviEW Financial Highlights 2 We want to discover, develop and News in 2012 3 successfully market innovative Letter from Daniel vasella 5 products to prevent and cure interview with Joseph Jimenez 11 diseases, to ease suffering and HEALTHcAREPORTFOLiO contents 17 to enhance the quality of life. Pharmaceuticals 21 Novartis institutes for Biomedical Research 33 We also want to provide a Alcon 37 shareholder return that reflects sandoz 47 outstanding performance and vaccines and Diagnostics 53 to adequately reward those consumer Health 59 who invest ideas and work in cORPORATE REsPONsiBiLiTy contents 65 our company. Expanding Access to Healthcare 67 Doing Business Responsibly 77 independent Assurance Report 85 cORPORATE GOvERNANcE contents 87 Our Board of Directors 96 Our management 110 cOmPENsATiON REPORT contents 121 compensation Report 122 NOvARTis GROUP FiNANciAL REPORT contents 147 Financial Highlights 2012 148 Key Financial Developments 149 Operating and Financial Review 150 shareinformation 168 summary of Key Financial Data 188 Novartis Group consolidated Financial statements 190 Financial statements of Novartis AG 258 Annual Report Photography and Films 278 Key Dates 2013, contact information 280 and Forward-Looking statements 1 GROUP REviEW Novartis provides healthcare solutions that address the evolving needs of patients and societies worldwide. Our portfolio focuses on broad areas of healthcare: pharmaceuticals, eye care, generics, vaccines, consumer-based OTc and animal health. FiNaNcial
    [Show full text]
  • The Sky Bar's Triumphant Return
    DEVRA FIRST The Sky Bar’s triumphant return How an iconic candy was almost lost and then, unexpectedly, saved By Devra First Globe Staff,Updated November 13, 2019, 6:00 a.m. Sky Bars are being made again locally, thanks to Louise Mawhinney who bought new equipment and the Sky Bar name from Necco when it closed. They're made at a new storefront location on Boston Post Road in Sudbury. JOHN TLUMACKI/GLOBE STAFF SUDBURY — All of this might have been lost. The futuristic red logo, shooting across the bright yellow background. The impeccable aesthetics, a bar of chocolate divided into four sections, each sloping downward toward the next, etched in a fanlike pattern. The you-can-have-it-all gratification of one candy with a quartet of fillings: caramel, vanilla, peanut, fudge. New England Confectionery Co.'s Sky Bar: born 1938, defunct 2018, the year Necco closed, putting all of its brands up for auction. Most went to experienced operators. Sweethearts Candies and Necco Wafers were purchased by the century-old Spangler Candy Company, perhaps best known for its tangerine-colored, mysteriously banana-flavored Circus Peanuts. Boyer Candy Company (Mallo Cups), started during the Great Depression, snapped up Clark Bars. But Sky Bar? Sky Bar became the property of Louise Mawhinney, a former biotech executive originally from Scotland who runs an eclectic gourmet gift shop called Duck Soup in Sudbury, Mass. She had never made candy before, but a customer told her about the auction and she just couldn’t let Sky Bar disappear. Louise Mawhinney and her son, Frank Mawhinney, make Sky Bars at their storefront location on Boston Post Road in Sudbury.
    [Show full text]
  • “Jack” Emerson: Volume V, Number 1 ______Founder of the J
    Winter 2005 Our Centennial Year The Newetowne Chronicle/ 1 IN THIS ISSUE P E O P L E A N D P L A C E S Winter 2005 The Remarkable John “Jack” Emerson: Volume V, Number 1 _________________________ Founder of the J. H. Emerson Company By Daphne Abeel P E O P L E A N D P L A C E S The Remarkable John ―Jack‖ Emerson When Will and George Emerson begin to talk about their family background cover story and their father, who founded the J. H. Emerson Company, they mention somewhat offhandedly that they are descended from a brother of Ralph Waldo The Lost Diners of Cambridge Emerson and that their paternal grandfather was related to the artist Maxfield page 8 Parrish. But it is only when they begin to describe their father, John ―Jack‖ F R O M T H E P R E S I D E N T Emerson, that their interesting and remarkable family legacy becomes clear. The First Century page 2 Today, the J. H. Emerson Company, now run by Will and George, is tucked away in a beautiful, well-lit, old brick warehouse on a dead-end street in F R O M T H E D I R E C T O R North Cambridge. When Jack Emerson started the company, in 1928, it was A Vision for the Second Century page 3 located at 15 Brattle Street, above what was once Woolworth’s. While two of his brothers had graduated from Harvard in the field of medicine, Jack was a S O C I E T Y N E W S high school dropout.
    [Show full text]